Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Hydrus microstent reduces intraocular pressure in patients with open-angle glaucoma in combination with cataract surgery: 36 month results from the SPECTRUM global hydrus registry

Poster Details

First Author: A. Fea ITALY

Co Author(s):    J. Garcia-Feijo   S. Gandolfi   M. Nardi   M. Rekas   P. de Waard        

Abstract Details


To assess intraocular pressure (IOP) and hypotensive medication changes after implantation of a dilating Schlemm’s canal scaffold (Hydrus Microstent) in a real-world, heterogeneous glaucoma cohort through a follow-up period of 36 months.


Multi-center, open-label post-market registry, with patients from 7 European centers in Italy, Spain, Netherlands, and Poland.


Patients with age-related cataracts and open-angle glaucoma were implanted with the Hydrus Microstent, and were followed for 36 months postoperatively. Patients ranged from mild-moderate to refractory glaucoma. Patients were followed under current standard of care. Prior to surgery, data was collected on pertinent medical and ocular history, glaucoma diagnosis, IOP, medication use, best-corrected visual acuity, visual field, and cup-to-disc ratio. Postoperatively, data was collected on IOP, medication use, and adverse events.


Fifty-five patients underwent combined phacoemulsification and Hydrus Microstent implantation. Preoperatively, mean IOP was 21.8 ± 8.7mmHg, with mean medications of 1.91 ± 1.0. Postoperatively, IOP decreased to 16.4 ± 2.7 mmHg on 0.47 ± 0.9 mean medications at 12 months, and to 16.0 ± 2.9 mmHg on 0.78 ± 1.0 mean medications at 36 months. At 36 months, 76.4% of patients had an IOP less than or equal to 18mmHg and 52.7% of patients were medication free.


Implantation of the Hydrus Microstent in combination with cataract surgery lowers IOP in patients with open-angle glaucoma in a real-world setting, and offers a continuous, durable alternative to medical therapy for IOP reduction in a wide range of glaucoma severity.

Financial Disclosure:


Back to Poster listing